C-FDAP

FILE C-FDAP·COMPANY·CURATED BY ETERNAL SEARCH

Olatec

NLRP3 antagonists, inflammasome inhibition, oral therapeutics

modulatingsmall molecule

olatec.com·New York City, New York, United States; Boston, Massachusetts, United States·$40M total funding

0-100 chain-logic scale · 15 dimensions · scored on public evidence